Threshold Pharmaceuticals, Inc. (THLD) Reports Promising Results in Phase 1 Trial for Leukemia
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in most solid tumors as well as the bone marrows of some hematologic tumors. The company announced today clinical trial results of the Phase 1 study of TH-302 in patients with advanced leukemia. Thirty-two patients with either acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) have been enrolled in the trial so far. The study is taking place at the MD Anderson Cancer Center in Houston, Texas. The starting dose in the trial was 120 mg/m2…